

Table 2: Eligibility Criteria

| S. No. | Name of KSM/DI/API | Minimum annual production Capacity (MT) | Threshold investment (Cr) | Maximum number of eligible manufacturer |
|---|-------------------------------|--|----------------------------------|--|
| Key Fermentation based KSMs/Drug Intermediates | | | | |
| 1. | Penicillin G | 5000 | 400 | 2 |
| 2. | 7- ACA | 1000 | 400 | 2 |
| 3. | Erythromycin Thiocynate(TIOC) | 800 | 400 | 2 |
| 4. | Clavulanic Acid | 1.5 lakh Kg | 400 | 2 |
| Fermentation based niche KSMs/Drug Intermediates /APIs | | | | |
| 5. | Neomycin | 175 | 50 | 2 |
| 6. | Gentamycin | 40 | 50 | 2 |
| 7. | Betamethasone | 2 | 50 | 2 |
| 8. | Dexamethasone | 2 | 50 | 2 |
| 9. | Prednisolone | 15 | 50 | 2 |
| 10. | Rifampicin | 100 | 50 | 2 |
| 11. | Vitamin B1 | 200 | 50 | 2 |
| 12. | Clindamycin Base | 60 | 50 | 2 |
| 13. | Streptomycin | 50 | 50 | 2 |
| 14. | Tetracycline | 450 | 50 | 2 |
| Key Chemical Synthesis based KSMs/Drug Intermediates | | | | |

| | | | | |
|--|-------------------------------------|------|----|---|
| 15. | 1,1 Cyclohexane Diacetic Acid (CDA) | 1500 | 50 | 4 |
| 16. | 2-Methyl-5Nitro-Imidazole (2-MNI) | 800 | 50 | 4 |
| 17. | Dicyandiamide (DCDA) | 8000 | 50 | 4 |
| 18. | Para amino phenol | 8000 | 50 | 4 |
| Other Chemical Intermediates/APIs Synthesis based KSMs/Drug | | | | |
| 19. | Meropenem | 10 | 20 | 4 |
| 20. | Atorvastatin | 30 | 20 | 4 |
| 21. | Olmesartan | 25 | 20 | 4 |
| 22. | Valsartan | 25 | 20 | 4 |
| 23. | Losartan | 80 | 20 | 4 |
| 24. | Levofloxacin | 115 | 20 | 4 |
| 25. | Sulfadiazine | 20 | 20 | 4 |
| 26. | Ciprofloxacin | 300 | 20 | 4 |
| 27. | Ofloxacin | 100 | 20 | 4 |
| 28. | Norfloxacin | 15 | 20 | 4 |
| 29. | Artesunate | 35 | 20 | 4 |
| 30. | Telmisartan | 80 | 20 | 4 |
| 31. | Aspirin | 2800 | 20 | 4 |
| 32. | Diclofenac Sodium | 175 | 20 | 4 |
| 33. | Levetiracetam | 140 | 20 | 4 |
| 34. | Carbidopa | 2 | 20 | 4 |
| 35. | Ritonavir | 5 | 20 | 4 |
| 36. | Lopinavir | 7 | 20 | 4 |

| | | | | |
|------------|---------------|-----|----|---|
| 37. | Acyclovir | 175 | 20 | 4 |
| 38. | Carbamazepine | 65 | 20 | 4 |
| 39. | Oxcarbazepine | 65 | 20 | 4 |
| 40. | Vitamin B6 | 35 | 20 | 4 |
| 41. | Levodopa | 10 | 20 | 4 |

Note: The Net Worth of the Applicant (including that of Group Companies), as on the date of application, shall not be less than 30% of the total proposed investment. The Applicant not meeting the said Net Worth criteria shall not be eligible